{"symbol":"SH600276","secucode":"600276.SH","items":[{"title":"恒瑞医药：关于药品上市许可申请获EMA受理的提示性公告","summary":"证券日报网讯10月8日，恒瑞医药发布公告称，公司近日收到欧洲药品管理局（EMA）通知，EMA正式确认并受理公司递交的氟唑帕利胶囊的上市许可申请，这是公司第二款自主研发的创新药向欧盟递交上市申请。拟定适应症（或功能主治）：氟唑帕利联合醋酸阿比特龙和泼尼松或泼尼松龙用于治疗转移性去势抵抗性前列腺癌（mCRPC）成年患者。氟唑帕利已于2020年12月在国内获批上市。","source":null,"url":"http://hk.eastmoney.com/news/11362,202610083889851881.html","info_code":"NW202610083889851881","show_time_timestamp":1791462300000,"show_time":"2026-10-08 20:25:00","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202610083889851881.html","url":"http://hk.eastmoney.com/news/11362,202610083889851881.html","code":"202610083889851881","infoCode":"NW202610083889851881","recordId":null,"source":null,"title":"恒瑞医药：关于药品上市许可申请获EMA受理的提示性公告","updateTime":0,"showDateTime":1791462300000,"publishDate":0,"sRatingName":null,"summary":"证券日报网讯10月8日，恒瑞医药发布公告称，公司近日收到欧洲药品管理局（EMA）通知，EMA正式确认并受理公司递交的氟唑帕利胶囊的上市许可申请，这是公司第二款自主研发的创新药向欧盟递交上市申请。拟定适应症（或功能主治）：氟唑帕利联合醋酸阿比特龙和泼尼松或泼尼松龙用于治疗转移性去势抵抗性前列腺癌（mCRPC）成年患者。氟唑帕利已于2020年12月在国内获批上市。"}},{"title":"恒瑞医药：9月份回购公司股份58.5万股","summary":"证券日报网讯10月8日，恒瑞医药发布公告称，2026年9月，公司通过上海证券交易所交易系统以集中竞价交易方式回购A股股份58.5万股，已回购股份占公司总股本的比例为0.009%，购买的最高价为人民币45.54元/股，最低价为人民币43.10元/股，已支付的总金额为人民币2,587.59万元（不含交易费用）。","source":null,"url":"http://stock.eastmoney.com/news/11215,202610083889851539.html","info_code":"NW202610083889851539","show_time_timestamp":1791462300000,"show_time":"2026-10-08 20:25:00","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202610083889851539.html","url":"http://stock.eastmoney.com/news/11215,202610083889851539.html","code":"202610083889851539","infoCode":"NW202610083889851539","recordId":null,"source":null,"title":"恒瑞医药：9月份回购公司股份58.5万股","updateTime":0,"showDateTime":1791462300000,"publishDate":0,"sRatingName":null,"summary":"证券日报网讯10月8日，恒瑞医药发布公告称，2026年9月，公司通过上海证券交易所交易系统以集中竞价交易方式回购A股股份58.5万股，已回购股份占公司总股本的比例为0.009%，购买的最高价为人民币45.54元/股，最低价为人民币43.10元/股，已支付的总金额为人民币2,587.59万元（不含交易费用）。"}},{"title":"摩根大通在恒瑞医药的H股好仓比例下降0.38%至9.87%","summary":"南财智讯10月8日电，香港交易所披露信息显示，JPMorganChase&Co.（摩根大通）在恒瑞医药的H股好仓（L）比例于10月5日从10.25%下降至9.87%。同时淡仓（S）比例从4.64%降至3.33%。","source":null,"url":"http://finance.eastmoney.com/news/1354,202610083889711818.html","info_code":"NW202610083889711818","show_time_timestamp":1791451140000,"show_time":"2026-10-08 17:19:00","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202610083889711818.html","url":"http://finance.eastmoney.com/news/1354,202610083889711818.html","code":"202610083889711818","infoCode":"NW202610083889711818","recordId":null,"source":null,"title":"摩根大通在恒瑞医药的H股好仓比例下降0.38%至9.87%","updateTime":0,"showDateTime":1791451140000,"publishDate":0,"sRatingName":null,"summary":"南财智讯10月8日电，香港交易所披露信息显示，JPMorganChase&Co.（摩根大通）在恒瑞医药的H股好仓（L）比例于10月5日从10.25%下降至9.87%。同时淡仓（S）比例从4.64%降至3.33%。"}},{"title":"美国资本集团在恒瑞医药H股的持股比例于10月6日从11.19%降至10.96%","summary":"香港交易所信息显示，美国资本集团在恒瑞医药H股的持股比例于10月6日从11.19%降至10.96%，卖出的平均股价为48.3868港元。","source":null,"url":"http://finance.eastmoney.com/news/1354,202610083889696480.html","info_code":"NW202610083889696480","show_time_timestamp":1791450377000,"show_time":"2026-10-08 17:06:17","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202610083889696480.html","url":"http://finance.eastmoney.com/news/1354,202610083889696480.html","code":"202610083889696480","infoCode":"NW202610083889696480","recordId":null,"source":null,"title":"美国资本集团在恒瑞医药H股的持股比例于10月6日从11.19%降至10.96%","updateTime":0,"showDateTime":1791450377000,"publishDate":0,"sRatingName":null,"summary":"香港交易所信息显示，美国资本集团在恒瑞医药H股的持股比例于10月6日从11.19%降至10.96%，卖出的平均股价为48.3868港元。"}},{"title":"恒瑞医药：药品上市许可申请获EMA受理","summary":"恒瑞医药(600276)10月8日公告，公司收到了欧洲药品管理局（简称“EMA”）的通知,EMA正式确认并受理公司递交的氟唑帕利胶囊的上市许可申请，这是公司第二款自主研发的创新药向欧盟递交上市申请。","source":null,"url":"http://stock.eastmoney.com/news/11215,202610083889700761.html","info_code":"NW202610083889700761","show_time_timestamp":1791450196000,"show_time":"2026-10-08 17:03:16","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202610083889700761.html","url":"http://stock.eastmoney.com/news/11215,202610083889700761.html","code":"202610083889700761","infoCode":"NW202610083889700761","recordId":null,"source":null,"title":"恒瑞医药：药品上市许可申请获EMA受理","updateTime":0,"showDateTime":1791450196000,"publishDate":0,"sRatingName":null,"summary":"恒瑞医药(600276)10月8日公告，公司收到了欧洲药品管理局（简称“EMA”）的通知,EMA正式确认并受理公司递交的氟唑帕利胶囊的上市许可申请，这是公司第二款自主研发的创新药向欧盟递交上市申请。"}}]}